With nearly 40 years of pharmaceutical R&D experience, David Evans provides deep global and cross-functional expertise. Holding a Ph.D. in Chemistry, metabolism, and toxicology from the University of Nottingham, he has authored over 50 peer-reviewed publications. His career includes executive leadership roles at GlaxoWellcome, Merck, and Johnson & Johnson, where he served as VP and Global Head of DMPK-PD-Bioanalysis and contributed to programs in all therapeutic areas. He is currently a consultant for biotech where he specializes in translational quantitative pharmacology, mechanistic toxicology, structure optimization, and product development, guiding companies through complex R&D challenges.

David supports Allegria with his expertise in DMPK & PD translational sciences.

Connect on LinkedIn.